Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions - Takeaways - MDSpire

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions

  • By

  • Hee Bum Jo

  • Jong Su Kang

  • Sungim Choi

  • Seong Yeon Park

  • May 25, 2026

  • 0 min

Share

  • 1

    A 47-year-old woman with neuromyelitis optica developed prolonged COVID-19 pneumonia after receiving rituximab, leading to recurrent hospital admissions.

  • 2

    Despite standard antiviral therapy, the patient experienced clinical deterioration, prompting the use of intravenous immunoglobulin (IVIG) as salvage therapy.

  • 3

    IVIG treatment resulted in rapid clinical improvement and complete resolution of the patient's oxygen requirement.

  • 4

    Serologic analyses showed undetectable SARS-CoV-2-specific IgG before IVIG, with significant increases in antibody titers following treatment.

  • 5

    The findings suggest that IVIG may restore immune effector functions in patients with B-cell depletion, aiding in the management of persistent COVID-19.

Original Source(s)

Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions

  • by Hee Bum Jo, Jong Su Kang, Sungim Choi, Seong Yeon Park

  • May 25, 2026

Related Content

Acute liver failure and secondary TMA-like phenomenon following SARS-CoV-2 and Mycoplasma pneumoniae co-detection in a child: a case report

Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis

Long COVID Persistence and Surveillance Gaps Across 58 US Hospitals